Skip to main content

Table 3 Results of outcome measures at baseline (N = 114)

From: Effects of motivational interviewing-based adherence therapy for schizophrenia spectrum disorders: a randomized controlled trial

Outcome measures

AT

TAU

Unpaired t test

P

 

(n = 57)

(n = 57)

 

M

SD

M

SD

ITAQ (0–22)a

9.12

6.14

9.33

3.31

1.52

0.20

PANSS

      

Total score (30–210)a

80.19

11.10

81.13

12.01

1.71

0.18

Positive symptoms (7–49)a

15.39

5.12

15.11

5.01

  

Negative symptoms (7–49)a

16.31

5.87

16.45

6.87

  

General psychopathology (16–112)a

48.49

9.12

49.57

9.88

  

SLOF

      

Total score (43–215)a

140.01

18.22

138.34

17.18

1.49

0.20

Self-maintenance(12–60)a

42.11

5.52

40.18

7.08

  

Social functioning (14–70)a

42.00

5.88

43.01

6.91

  

Community living skills (17–85)a

55.90

8.01

55.15

8.33

  

Adherence rating scale (1–5)a

1.48

0.98

1.39

1.01

1.92

0.12

Total non-adherence (f, %)

(22, 38.80)

(20, 35.09)

χ2 = 1.48

0.13

  

Poor to inadequate adherence (f, %)

(28, 49.12)

(29, 50.88)

    

Fair to good adherence (f, %)

(7, 12.28)

(8, 14.04)

    

Re-hospitalization

      

Numberb

1.41

0.98

1.50

0.92

1.83

0.12

Durationc

9.12

3.98

10.01

4.02

2.33

0.10

DAI (0–22)a

8.82

3.03

9.01

3.71

1.51

0.13

  1. AT: Adherence therapy, DAI: Drug Attitude Inventory, ITAQ: Insight and Treatment Attitude Questionnaire, PANSS: Positive and Negative Syndrome Scale, SLOF: Specific Levels of Functioning Scale, TAU: Treatment as usual
  2. aPossible range of score in each measure in the parentheses. bAverage number of readmissions to a psychiatric hospital or inpatient unit in the past four months. cDuration of psychiatric readmissions at each time point in terms of average number of days of hospital stay over the past four months